Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells.

Scientific reports - 2 Oct 2024

Li Lanxin, Liu Chenyang, Wang Rui, Yang Xiaolin, Wei Xiangkai, Chu Chunhong, Zhang Guoliang, Liu Chenxue, Cui Wenrui, Xu Huixia, Wang Ke, An Lei, Li Xiaodong

Abstract excerpt

Mutations in the epidermal growth factor receptor (EGFR) gene are common driver oncogenes in non-small cell lung cancer (NSCLC). Studies have shown that afatinib is beneficial for NSCLC patients with rare EGFR mutations. However, the effectiveness of tyrosine kinase inhibitors (TKIs) against the G719X (G719A, G719C and G719S) mutation has not been fully established. Herein, using the CRISPR method, the EGFR G719X...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to ErbB Receptors

Share to Lung Neoplasms

Share to MAP Kinase Signaling System

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Source

Open in PubMed Open full text

Identifiers

PMID: 39358400
DOI: 10.1038/s41598-024-73293-z
PMCID: PMC11447065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells.PMID 39358400Read ↗

Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells.Semantic proximity Read ↗

Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation.Semantic proximity Read ↗

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Semantic proximity Read ↗

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung CancerSemantic proximity Read ↗

BDTX-189, a novel tyrosine kinase inhibitor, inhibits cell activity via ERK and AKT pathways in the EGFR C797S triple mutant cells.Semantic proximity Read ↗

Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.Semantic proximity Read ↗

Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.Semantic proximity Read ↗

LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.Semantic proximity Read ↗

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

CRISPR-mediated modulation of EGFR signaling in lung cancer.Semantic proximity Read ↗

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.